Alteration of gene expression by alcohol exposure at early neurulation

Feng C Zhou1*, Qianqian Zhao2, Yunlong Liu2, Charles R Goodlett4, Tiebing Liang2, Jeanette N McClintick3, Howard J Edenberg3, Lang Li2

Abstract

Background: We have previously demonstrated that alcohol exposure at early neurulation induces growth retardation, neural tube abnormalities, and alteration of DNA methylation. To explore the global gene expression changes which may underlie these developmental defects, microarray analyses were performed in a whole embryo mouse culture model that allows control over alcohol and embryonic variables.

Result: Alcohol caused teratogenesis in brain, heart, forelimb, and optic vesicle; a subset of the embryos also showed cranial neural tube defects. In microarray analysis (accession number GSM9545), adopting hypothesis-driven Gene Set Enrichment Analysis (GSEA) informatics and intersection analysis of two independent experiments, we found that there was a collective reduction in expression of neural specification genes (neurogenin, Sox5, Bhlhe22), neural growth factor genes [Igf1, Efemp1, Klf10 (Tieg), and Edil3], and alteration of genes involved in cell growth, apoptosis, histone variants, eye and heart development. There was also a reduction of retinol binding protein 1 (Rbp1), and de novo expression of aldehyde dehydrogenase 1B1 (Aldh1B1). Remarkably, four key hematopoiesis genes (glycophorin A, adducin 2, beta-2 microglobulin, and ceruloplasmin) were absent after alcohol treatment, and histone variant genes were reduced. The down-regulation of the neurospecification and the neurotrophic genes were further confirmed by quantitative RT-PCR. Furthermore, the gene expression profile demonstrated distinct subgroups which corresponded with two distinct alcohol-related neural tube phenotypes: an open (ALC-NTO) and a closed neural tube (ALC-NTC). Further, the epidermal growth factor signaling pathway and histone variants were specifically altered in ALC-NTO, and a greater number of neurotrophic/growth factor genes were down-regulated in the ALC-NTO than in the ALC-NTC embryos.

Conclusion: This study revealed a set of genes vulnerable to alcohol exposure and genes that were associated with neural tube defects during early neurulation.
and Fabp4; [20]), nucleotide excision repair gene, (Ercc6l) [23], stress-related genes (e.g. heat shock protein 47 [24]), and differentiation and apoptosis genes such as Timp4, Bmp15, Rnf25, Akt1, Tulp4, Dextra1 [25]. These altered genes suggest potential mechanisms for the abnormal development in FASD. However, the wide-ranging developmental abnormalities in FASD are likely a consequence of the interaction of multiple genes. Examination of global gene expression provides a holistic view of genes that potentially interact and collaboratively contribute to the abnormal development. Alcohol exposure induced changes in a group of cellular adhesion genes (e.g. L1cam and integrin) in neuroblastoma cells [26]. A brief ethanol exposure (3 h) at gestation day 8 (E8) in mouse embryos altered expression of genes of metabolic, cell programming and cytoskeletal signaling pathways [27]. An earlier alcohol exposure at E6-E8 also altered a set of genes related to PLUNC, neurofilament, and pale ear [28].

In animal models of prenatal alcohol exposure, sources of variability include the pattern, concentration, amount, and developmental stage of alcohol exposure, maternal stress, embryonic growth and maturation of embryos between litters and even within a given litter and within inbred strains of mice [29]. Control of all these variables in rapidly developing embryos is virtually unattainable in vivo. To limit these variables, a whole embryonic culture [30,31] was adopted, including stage alignment based on somite number, in which the pattern, amount and concentration of alcohol and embryonic staging were controlled. Inbred C57BL/6 mice, with known susceptibility to ethanol teratogenesis [32,33], were used for this study.

Differences in the dose and timing of alcohol exposure are known contributors to variation in the phenotypic spectrum in FASD. Understanding the pattern of gene alterations that co-vary with different outcomes produced by different alcohol doses or developmental timing of exposure would provide valuable insights into mechanisms underlying this phenotypic variability. As development is highly dynamic throughout gestation, we asked how alcohol exposure might affect genome-wide gene expression at the critical stage of neurulation (E8-10), when the nervous system (and other major organs) are actively forming in mouse. We have shown that at this key stage, neural tube formation was highly sensitive to the alcohol insult [29]. DNA methylation was altered, with the degree of change commensurate with severity of neural tube defect [34]. In the current study, in an initial experiment, cluster analysis indicated distinct differences in gene expression not only between control- and alcohol-treated embryos, but also between two phenotypic subsets of alcohol-treated embryos discernable at the end of alcohol treatment, one group which had a closed neural tube (ALC-NTC) and the other group with an open neural tube (ALC-NTO). A second study with a larger set of arrays was then performed in which alcohol-treated embryos of both neural tube phenotypes were specifically compared. We report here the correlation of alcohol-induced embryonic growth retardation and neural tube abnormalities with changes in expression in networks of genes known to regulate embryonic growth, organ development, and neural specification processes.

Results

Embryonic Growth Retardation/Abnormalities
As was seen in our previous report [29], the size and somite number varied (from 1-6) among embryos within a litter at the time of harvesting from the mother. We selected embryos of similar developmental stages (3-5 somites) and randomly assigned them to the two treatment groups (alcohol or control). The alcohol concentration profile of the culture media over the 46 hours was similar to that in our previous report [29]. The concentration of ethanol in the medium was ~88 mM at the start of each day (when first added to the media) and declined to ~44 mM by the end of each day. Among all cultured embryos, more than 95% maintained active heartbeats and blood circulation over this time, and only those were used for analysis. Development of the heart, caudal neural tube, brain vesicles, optic system, and limb buds in the embryos were significantly compromised in the alcohol treated group (Table 1). Brain vesicle development was retarded and the brain vesicles were smaller in size in the alcohol group. The significant effects in multiple organs and regions and in total scores (Table 1) demonstrated that alcohol treatment resulted in retardation of the overall growth and interfered with development of several specific structures, including brain, heart, and limb development, in this embryonic culture model.

The overall growth retardation was accompanied by varying degrees of abnormality in organ system development (Figure 1). These abnormalities included an increased size of the heart and ventricular chambers, reduced size of lung buds, flattened forebrain, small/slanted eyes, abnormal tail morphology, abnormal limb web, and unfinished turning of neural axis. A reduced blood/vascular system was also evident by less vascularization in yolk sac (Table 1), and lower red coloration apparent in many blood vessels of yolk sacs and embryos in the alcohol-treated than the control embryos (Figure 2).

Among 127 samples of alcohol-treated embryos, 34 (27%) had various degrees of incomplete neural tube closing (Figure 1); this compares to 3 (2%) out of the 139 controls. These openings in the neural tube mostly
occurred in the head fold, although delayed or incomplete neural tube closure in midbrain and hindbrain was also seen. The abnormalities and developmental delays are clearly more severe in ALC-NTO than in ALC-NTC subgroups, particularly in development of the neural axis including hindbrain, midbrain, forebrain, otic vesicle.

Differences in Gene Expression

At the end of the culture period, the total RNA extracted from alcohol-treated embryos was approximately half that of controls: controls = 2.8 ± 0.5 (n = 13), ALC-NTC = 1.6 ± 0.5 (n = 13, P < 0.05 compared with control), ALC-NTO = 1.2 ± 0.5 (n = 8, P < 0.05 compared with control). In Experiment 1, 14,243 out of 22,690 probe sets (62.7%) were present in at least half of the samples in either control or alcohol treated groups. Hierarchical clustering by arrays (Figure 3. Exp 1) clearly separated the samples into three groups, control, ALC/NTC, and ALC/NTO, rather than just two (ALC vs. control). In Experiment 2, 26,674 out of 45101 probe sets (59.1%) were present in at least half of the samples in either control or alcohol treated group. Again, the hierarchical cluster analysis (Figure 3. Exp 2) separated the samples into the same three groups, control, ALC/NTC, and ALC/NTO.

In Experiment 1, 850 probe sets (6% of the probe sets that were present) were differentially expressed in alcohol-treated embryos as a group (p ≤ 0.05). In Experiment 2, which had more power due to the larger number of arrays and also examined twice as many probe sets, 2519 probe sets (9.4% of the probe sets that were present) were differentially expressed in alcohol-treated embryos considered as a group (p ≤ 0.05). These relaxed stringencies were employed to reduce false negatives when comparing genes across the two experiments. The probe sets on the Mouse Genome 430A GeneChip were a subset of those on the Mouse Genome 430 2.0 GeneChip. Comparing this common subset across the two experiments, 87 probe sets were significant in both experiments and consistent in direction; because there are 13810 genes present in both experiments, the null expectation is that only 17 genes would be expected to be in common with the same direction of change. 49 probe sets were lower in alcohol-treated embryos and 38 were higher (Table 2). Among these were genes for alcohol metabolism, epigenetics (histone and histone variants), hematopoiesis, neurotrophic factors, retinol metabolism, cell cycle, cell adhesion, homeobox genes, and oncogenes.

Furthermore, in Experiment 2 (which had more power to detect differences), a number of genes in addition to the above list were present in the controls but were absent in the alcohol treated samples (Table 3). Notably, glycoporphin A (Gypa) and beta-2 microglobulin (B2m) genes were absent in ALC-NTO, and ceruloplasmin (Cp), adducin 2 (Add2), B2 m, and ceruloplasmin (Cp) genes were absent in ALC-NTC. All of these are critical in hematopoiesis and/or red blood cell function [35-39]. In contrast, the aldehyde dehydrogenase 1 family, B1 (Aldh1b1), which catalyzes oxidation of retinaldehyde, was present only in the alcohol-treated embryos with

| Region                        | Control | Alcohol | ALC-NTC | ALC-NTO |
|-------------------------------|---------|---------|---------|---------|
| Allantois                     | 3 ± 0   | 2.80 ± 0.08 | 2.86 ± 0.10 | 2.70 ± 0.14 |
| Branchial bars                | 2.77 ± 0.09 | 2.15 ± 0.21 | 2.17 ± 0.26 | 2.11 ± 0.39 |
| Brain: Forebrain              | 4.76 ± 0.10 | 3.81 ± 0.27* | 4.57 ± 0.14 | 2.29 ± 0.29** ^^ |
| Brain: Midbrain               | 4.52 ± 0.11 | 3.71 ± 0.27 | 4.50 ± 0.14 | 2.14 ± 0.14** ^^ |
| Brain: Hindbrain              | 4.71 ± 0.10 | 3.86 ± 0.24* | 4.50 ± 0.14 | 2.57 ± 0.30** ^^ |
| Caudal Neural Tube            | 4.76 ± 0.12 | 4.11 ± 0.19* | 4.09 ± 0.26* | 4.14 ± 0.26* |
| Flexion                       | 4.80 ± 0.09 | 4.33 ± 0.19 | 4.59 ± 0.19 | 3.81 ± 0.36* |
| Heart                         | 4.80 ± 0.10 | 4.10 ± 0.16** | 4.15 ± 0.19* | 4.00 ± 0.31* |
| Limb: Forelimb                | 2.01 ± 0.06 | 1.51 ± 0.13** | 1.48 ± 0.18* | 1.57 ± 0.20 |
| Limb: Hindlimb                | 0.53 ± 0.10 | 0.20 ± 0.08* | 0.21 ± 0.09 | 0.19 ± 0.14 |
| Mandibular process            | 2.08 ± 0.11 | 1.99 ± 0.09 | 2.12 ± 0.08 | 1.71 ± 0.18 |
| Maxillary process             | 2.41 ± 0.14 | 2.06 ± 0.16 | 2.21 ± 0.18 | 1.76 ± 0.30 |
| Olfactory system              | 0.47 ± 0.08 | 0.26 ± 0.08 | 0.29 ± 0.11 | 0.20 ± 0.13 |
| Optic system                  | 3.59 ± 0.14 | 2.87 ± 0.14** | 3.02 ± 0.17* | 2.57 ± 0.20** |
| Otic system                   | 3.95 ± 0.12 | 3.68 ± 0.11 | 3.88 ± 0.10 | 3.29 ± 0.18* ^ |
| Somites                       | 4.81 ± 0.09 | 4.38 ± 0.16 | 4.50 ± 0.17 | 4.14 ± 0.34 |
| Total score                   | 53.97 ± 0.66 | 45.83 ± 1.54** | 49.14 ± 1.54** | 39.23 ± 1.72** ^^ |

* P-Value <0.05, ** <0.01; compared to control.
^ P-Value <0.05, ^^ <0.01; compared to NTC.
Control n = 21; Alcohol (all alcohol-treated, n = 21; ALC-NTC, n = 14; ALC-NTO, n = 7).
open neural tubes (ALC-NTO) (Table 3 last row). No gene was found to be absent in Control but present in ALC-NTC. Another retinol regulating gene, cellular retinol binding protein 1 (Crbp1), was reduced by alcohol exposure (Table 2).

**Gene Set Enrichment Analysis (GSEA) Analyses**

Four GSEA analyses were conducted within each experiment: control versus all alcohol-treated (ALC), control versus ALC-NTC, control versus ALC-NTO, and ALC-NTC versus ALC-NTO. As 415 GO gene sets and 191 stem cell related gene set were pre-selected, there were totally $4 \times (415+191) = 2424$ GSEA tests. We found 15 gene sets that were significant at 5% and shared the same enrichment direction in both experiments. By chance, one would expect only $2424 \times (0.05 \times 0.05 \times 0.5) = 3$; therefore, the FDR is $3/15 = 20\%$. The significant gene sets common to the two experiments are outlined below.

**a. Early Developmental Biology Gene Sets**

GSEA analysis using the GO biological function categories selected as being related to development (Additional files 1 and 2) identified 20 enriched sets in Experiment 2. Of these 20 sets, 9 were also identified by Experiment 1 (Table 4). Included in these shared gene sets are multiple GO categories related to growth, eye and heart development, and epigenetics. When comparing the control embryos to all alcohol treated embryos, there were 7 GO categories that were enriched in the control groups (i.e., down-regulated in the alcohol-treated

---

**Figure 1** Alcohol causes dysmorphology of growing embryos. Control embryos (a), Alcohol-treated (b-f). There are many dysmorphologies including microencephaly of forebrain (b, c, f), failure of closure of midbrain (mb; c) or hindbrain (hb; f), dysmorphic optical vesicle (optic; d), flex tail (ft; e) in caudal neural tube, delay formation of heart (H) chamber (b) and occasional detachment of epicardium (epic; b and d), neural tube opening at midbrain (mb; c, arrowheads) and hindbrain (hb; f, arrowheads) in the alcohol group. Majority of the brain vesicles in alcohol-treated group were closed (ALC-NTC; b, e). Approximately 30% of the embryos were found with a neural tube opening (ALC-NTO), usually in the head fold. Scale bars: a, b, c, e, f = 0.05mm; d = 0.25 mm.
five growth-related GO sets, one epigenetics (histone and chromatin regulator) GO set, and one angiogenesis GO set (Table 4). No gene set was enriched in the alcohol-treated group. An example of gene enrichment analysis is shown in Figure 4 for GO:0040007, Growth. This gene set contained 75 genes. The GSEA p-values for this enrichment score were 0.010 in Experiment 1 and 0.005 in Experiment 2.

The growth-related genes represented the largest group of affected genes. There were 5 GO sets of growth-associated genes (Table 4). Many of these genes, identified by GSEA in both experiments, were also identified in Experiment 2 at the single gene level; e.g. the Growth gene set (GO:0040007): Ctgf, Igfbp2, Emp1, Osm, Cyr61, Gap43, Crim1, Tgfb3, Nov, Socs2, and Wnt were significantly reduced in Experiment 2, and Igfbp7, Emp3, Bmp4, Bmp6, Inhbb, Wig1, and Cish were reduced but
Table 2 Genes with changed expression

| Gene symbol | UniGene | Source.id | Exp. 1 Fold Change | Exp. 2 Fold Change | Category/Function | Description |
|-------------|---------|-----------|--------------------|--------------------|-------------------|-------------|
| AI415282   | Mm.254704 | 1415793_at | -1.1               | -1.6               | expressed sequence| AI415282    |
| Atp6ap2     | Mm.25148  | 1439456_x_at | -1.2               | -1.2               | Energy            | ATPase, H+ transporting, lysosomal protein 2 |
| BC008163   | Mm.11473  | 1425328_at | -1.2               | -1.2               | CDNA sequence     | BC008163    |
| Cask        | Mm.253779 | 1427692_a_at | -1.5               | -1.1               | MAGUK family      | calcium/calmodulin-dependent serine protein kinase |
| Clk1        | Mm.1761   | 1426124_a_at | -1.6               | -1.3               | Cell cycle        | CDC-like kinase 1 |
| Clk4        | Mm.239534 | 1427663_a_at | -1.7               | -1.3               | Cell cycle        | CDC like kinase 4 |
| Crl1        | Mm.44244  | 1448406_at | -1.2               | -1.2               | DNA transcription/| predisposition to cancer |
| Crys1       | Mm.1231   | 1416039_x_at | -1.4               | -1.6               | extracellular matrix | Cysteine rich protein 61 |
| Dach2       | Mm.79760  | 1449823_at | -1.3               | -1.3               | Myogenin          | Dachshund 2 (Drosophila) |
| Ebf1        | Mm.255321 | 1416302_at | -1.5               | -1.4               | hematopoiesis     | early B-cell factor 1 |
| Ebf2        | Mm.319947 | 1449101_at | -1.2               | -1.4               | hematopoiesis     | early B-cell factor 2 |
| Ebf3        | Mm.30282  | 1428349_s_at | -1.5               | -1.3               | hematopoiesis     | early B-cell factor 3 |
| Edil3       | Mm.41716  | 1433474_at | -1.4               | -1.4               | Homeobox          | EGF-like repeats and discoidin I-like domains 3 |
| Efrmp1      | Mm.44176  | 1427183_at | -1.4               | -1.9               | Neurotrophin      | EGF-containing fibulin-like extracellular matrix protein 1 |
| Foxd1       | Mm.344741 | 1418876_at | -1.4               | -1.2               | Homeobox          | forkhead box D1 |
| Gypc        | Mm.292145 | 1423878_at | -1.2               | -1.4               | hematopoiesis     | glycoporin C |
| Hist1h3a    | Mm.221301 | 1429482_s_at | -1.6               | -1.3               | Epigenetic        | histone 1, H3a |
| Hist1h4i    | Mm.14775  | 144854_at  | -1.7               | -1.5               | Epigenetic        | histone 1, H4i |
| Hist3h2a    | Mm.212549 | 1435866_s_at | -2.1               | -1.7               | Epigenetic        | histone 3, H2a |
| Igl1        | Mm.268521 | 1419519_at | -1.4               | -1.3               | Neurotrophin      | insulin-like growth factor 1 |
| Lgals1      | Mm.43831  | 1419573_a_at | -1.4               | -1.7               | Angiogenesis/     | neural development |
| Mageh1      | Mm.6890   | 1422498_at | -1.3               | -1.3               | Oncogene          | Melanoma antigen, family H, 1 |
| Myct1       | Mm.33762  | 1452072_at | -1.3               | -1.3               | Oncogene          | myc target 1 |
| Napb        | Mm.274308 | 1423172_at | -1.6               | -1.4               | Synapsis          | N-ethylmaleimide sensitive fusion protein beta |
| Nrdg1       | Mm.30837  | 1423413_at | -1.9               | -1.8               | Cell cycle        | N-myc downstream regulated gene 1 |
| Pel1        | Mm.28957  | 1417371_at | -1.2               | -1.1               | Kinase            | Pellino 1 |
| Pim1        | Mm.328931 | 1435872_at | -1.3               | -1.3               | hematopoiesis     | provilal integration site 1 |
| Ppox        | Mm.300006 | 1416618_at | -1.3               | -1.3               | hematopoiesis     | protoporphyrogen oxidase |
| Pppr14a     | Mm.2343   | 1418086_at | -1.1               | -1.3               | signal transduction | Protein phosphatase 1, regulatory subunit 14A |
| Ptx3        | Mm.276776 | 1418666_at | -1.5               | -1.7               | plasma proteins   | pentaxin related gene |
| Rab11a      | Mm.1387   | 1449256_a_at | -1.1               | -1.2               | Oncogene          | RAB11a, member RAS oncogene family |
| Rbp1        | Mm.302504 | 1448754_at | -1.2               | -1.2               | Retinol metabolism | retinol binding protein 1, cellular |
| Rpl13a      | Mm.180458 | 1433928_a_at | -1.1               | -1.1               | Synthesis         | ribosomal protein L13a |
| Rpl17       | Mm.276337 | 1453752_at | -1.3               | -1.2               | Synthesis         | ribosomal protein L17 |
| Skil        | Mm.15406  | 1422054_a_at | -1.6               | -1.4               | Oncogene          | SK-like |
| Sncg        | Mm.282800 | 1417788_at | -4.4               | -1.5               | Oncogene          | synuclein, gamma |
| Snn2        | Mm.29580  | 1432382_at | -1.7               | -1.8               | Neural specification | Stathmin-like 2 |
| Snn3        | Mm.2319   | 1460181_at | -1.7               | -1.7               | Neural specification | Stathmin-like 3 |
| Syp1        | Mm.44207  | 1416472_at | -1.2               | -1.1               | Synapsis          | Synapse associated protein 1 |
| Timp3       | Mm.4871   | 1419089_at | -1.3               | -1.3               | Tissue inhibitor of metalloproteinase 3 |
| Ubex2b      | Mm.280233 | 1432107_at | -1.1               | -1.1               | Epigenetic        | ubiquitin-conjugating enzyme E2B, RAD6 homology |
| Vcam1       | Mm.76649  | 1448162_at | -1.3               | -1.3               | Cell adhesion     | Vascular cell adhesion molecule 1 |
| 1110008H02Rik | Mm.28311 | 1436506_a_at | -1.3               | -1.3               | Energy            | RIKEN cDNA 1110008H02 gene |
| 2010011120Rik | Mm.30013 | 1426495_at | -1.2               | -1.6               | Energy            | RIKEN cDNA 2010011120 gene |
| 2310034L04Rik | Mm.41891 | 1426416_a_at | -1.2               | -1.2               | RIKEN cDNA 2310034L04 gene |
| 5033414D02Rik | Mm.275511 | 1460361_at | -1.2               | -1.3               | RIKEN cDNA 5033414D02 gene |
| 5230400G24Rik | Mm.139716 | 1451572_a_at | -1.3               | -1.1               | RIKEN cDNA 5230400G24 gene |
| 5730420B22Rik | Mm.28129 | 1427050_at | -1.4               | -1.4               | RIKEN cDNA 5730420B22 gene |
did not reach the criteria for significance. The additional growth genes in Epidermal growth factor receptor (EGFR) signaling pathway GO group appear to be reduced to a greater extent in ALC-NTO than in ALC-NTC (Table 4).

b. Stem Cell Related Gene Sets
Three gene sets were enriched in the control embryos compared to the combined alcohol-treated embryos (i.e., down-regulated in the alcohol-treated group): TGF-Beta activin-responsive genes (important for maintenance of

| Gene Accession | Gene Symbol | Gene Description | Expression Ratio |
|----------------|-------------|------------------|------------------|
| A630082K20Rik | A630082K20 | RIKEN cDNA A630082K20 gene | -1.7 -1.3 |
| Mm.293175 | Mm.293175 | Lipid metabolism acyl-CoA synthetase long-chain family member 6 | 1.2 1.4 |
| Mm.267478 | Mm.267478 | Energy ATPase, Na+/K+ transporting, alpha 1 polypeptide | 1.2 1.2 |
| Mm.270088 | Mm.270088 | Membrane Transport expressed sequence AWS47356 | 1.2 1.2 |
| Mm.27090 | Mm.27090 | Amino acid metabolism carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase | 1.2 1.3 |
| Mm.305355 | Mm.305355 | Lipid metabolism carnitine deficiency-associated gene expressed in ventricle 3 | 1.2 1.2 |
| Mm.261205 | Mm.261205 | Cell adhesion Calcyntenin 1 | 1.2 1.2 |
| Mm.277582 | Mm.277582 | Protease activity carboxypeptidase D | 1.1 1.3 |
| Mm.277582 | Mm.277582 | Cell adhesion embigin | 1.1 1.2 |
| Mm.150972 | Mm.150972 | RNA degradation exosome component 2 | 1.1 1.2 |
| Mm.157190 | Mm.157190 | High mobility group AT-hook 2 | 1.2 1.1 |
| Mm.5079 | Mm.5079 | Steroid Metabolism Hydroxysteroid 11-beta dehydrogenase 2 | 1.4 1.4 |
| Mm.28366 | Mm.28366 | Protease activity Insulin degrading enzyme | 1.2 1.2 |
| Mm.253335 | Mm.253335 | interferon alpha responsive gene | 1.1 1.1 |
| Mm.132208 | Mm.132208 | Nuclear Protein Transport importin 11 | 1.2 1.2 |
| Mm.225096 | Mm.225096 | Cell adhesion integrin alpha 6 | 1.1 1.2 |
| Mm.41513 | Mm.41513 | Alcohol metabolism Kruppel-like factor 16 | 1.3 1.3 |
| Mm.290791 | Mm.290791 | Energy NADH dehydrogenase (ubiquinone) Fe-S protein 1 | 1.2 1.1 |
| Mm.25582 | Mm.25582 | Alcohol metabolism PHD finger protein 13 | 1.2 1.1 |
| Mm.28366 | Mm.28366 | hematopoiesis, kinase Podocalyxin-like | 1.3 1.3 |
| Mm.12194 | Mm.12194 | Proteasome Proteasome (prosome, macropain) 26 S subunit, non-ATPase, 3 | 1.1 1.2 |
| Mm.332840 | Mm.332840 | pentatricopeptide repeat domain 1 | 1.4 1.3 |
| Mm.168257 | Mm.168257 | Signal transduction ras homolog gene family, member U | 1.2 1.2 |
| Mm.135581 | Mm.135581 | RNA polymerase 1-4 | 1.2 1.1 |
| Mm.200941 | Mm.200941 | Lipid metabolism serum amyloid A 2 | 1.7 1.7 |
| Mm.89918 | Mm.89918 | Lipid metabolism solute carrier family 27 (fatty acid transporter), member 4 | 1.3 1.3 |
| Mm.12194 | Mm.12194 | Proteosome Proteasome (prosome, macropain) 26 S subunit, non-ATPase, 3 | 1.1 1.2 |
| Mm.332840 | Mm.332840 | pentatricopeptide repeat domain 1 | 1.4 1.3 |
| Mm.168257 | Mm.168257 | Signal transduction ras homolog gene family, member U | 1.2 1.2 |
| Mm.135581 | Mm.135581 | RNA polymerase 1-4 | 1.2 1.1 |
| Mm.200941 | Mm.200941 | Lipid metabolism serum amyloid A 2 | 1.7 1.7 |
| Mm.89918 | Mm.89918 | Lipid metabolism solute carrier family 27 (fatty acid transporter), member 4 | 1.3 1.3 |

Table 2 Genes with changed expression† (Continued)

†P < 0.05.
### Table 3 Genes in Experiment 2 that are turned on or off by alcohol treatment

| Gene Symbol | Genbank | p-value | Change in Alcohol-treated | Description |
|-------------|---------|---------|---------------------------|-------------|
| Add2*       | NM_013458 | 0.0196  | Off                        | Adducin 2 (beta) |
| B2m*        | NM_009735 | 0.0446  | Off                        | Beta-2 microglobulin |
| Cfi         | NM_007686 | 0.0494  | Off                        | Complement component factor i |
| Cp*         | NM_007752 | 0.0225  | Off                        | Ceruloplasmin |
| Fbxo2       | NM_176848 | 0.0290  | Off                        | F-box only protein 2 |
| Gch1        | NM_008102 | 0.0017  | Off                        | GTP cyclohydrolase 1 |
| Gfi1b       | NM_008114 | 0.0007  | Off                        | Growth factor independent 1B |
| Nppb        | NM_008726 | 0.0103  | Off                        | Natriuretic peptide precursor type B |
| Pitpnm1     | NM_008851 | 0.0272  | Off                        | Phosphatidylinositol membrane-associated 1 |
| Ppgb        | NM_008906 | 0.0044  | Off                        | Protective protein for beta-Galactosidase |
| Tacr2       | NM_009314 | 0.0108  | Off                        | Tachykinin receptor 2 |
| Acbd5       | NM_028793 | 0.0292  | Off                        | Acyl-Coenzyme A binding domain containing 5 |
| Frmd3       | NM_172869 | 0.0004  | Off                        | FERM domain containing 3 |
| Gypa*       | NM_010369 | 0.00001 | Off                        | Glycophorin A |
| Mrl1        | BB298201  | 0.0295  | Off                        | Mblkl-related protein-1 |
| Ogn         | NM_008760 | 0.0363  | Off                        | Osteoglycin |
| Pdc4        | BG230003  | 0.0468  | Off                        | Programmed cell death 4 |
| Sqstm1      | NM_011018 | 0.0357  | Off                        | Sequestosome 1 |
| Aldh1b1     | NM_028270 | 0.0048  | On                         | Aldehyde dehydrogenase 1 family, member B1 |

### Table 4 GSEA for Early Development Biology GO sets

| Comparison vs | Keyword | Gene Set Description | Size | p-value | Significant Genes | p-value |
|---------------|---------|----------------------|------|---------|-------------------|---------|
| Control vs ALC-NTO/ALC-NTC | Growth Regulation* | GO:0016049 Cell growth ^Growth | 47   | 0.002   | (Ctgf, Igfbp2, Emp1, Osm, Cyr61, Gap43, Crim1, Tgfβ3, Igfbp7, Nov, Emp3), Gpc3, Csf1, Socs2, Bmp6, Bmp4, Inhbb, Lepre1, Wnp, Wng1, Cish | 0.010  |
|               |         | GO:0040007 Growth Regulation of cell growth Regulation of growth | 39   | 0.002   | (Ctgf, Igfbp2, Osm, Cyr61, Gap43, Crim1, Igfbp7, Nov), Gpc3, Csf1, Socs2 | 0.006  |
|               |         | GO:0005520 Insulin-like growth factor binding | 14   | 0.000   | Ctgf, Igfbp2, Cyr61, Crim1, Igfbp7, Nov | 0.012  |
| Heart*        |         | GO:0001525 Angiogenesis | 53   | 0.022   | Ctgf, Anxa2, Cyr61, Thbs1, Vgfa, Tie1, Elk3, Fli1, Chr1, Vegfc, Kdr, Bmp4, Adra2b, Tnfsf12a | 0.022  |
| Epigenetic factor~^  |         | GO:0003634 Nucleosome modeling | 30   | 0.021   | Hist1h2a, a; Hist1h3f; Hist1h1c; Hist1h2b, c; Hist1h3a; H1f0; Smarca2; Nap113 | 0.033  |

^ = Gene set reduced in ALC-NTO as compared with Control.
* = Gene sets reduced in ALC (all alcohol group) and ALC-NTC as compared with Control.
~ = Gene set reduced in ALC-NTC as compared with Control.
( ) = genes in Cell growth related GO set, which is included in Growth GO set; or genes in Regulation of Cell growth related GO set, which is included in Regulation of Growth GO set.
pluripotency and embryonic stem cells [40]), extracellular matrix (ECM) molecules, and ECM protease inhibitors (Table 5). Two gene sets were down-regulated in the ALC-NTO group (enriched in the control group): other related growth factor and other ECM molecules (Table 5). There were no significant gene sets in comparisons between ALC-NTC and ALC-NTO. No gene set was enriched in any alcohol-treated group.

Table 5 GSEA for Stem Cell Related Gene Sets

| Comparison       | Gene Set                                                   | Size | p-value Exp. 2 | Significant Genes                                                                 | p-value Exp. 1 |
|------------------|------------------------------------------------------------|------|----------------|-----------------------------------------------------------------------------------|----------------|
| Control vs ALC   | Other ECM Molecules^                                  | 9    | 0.002          | Ctgf, Thbs2, Tgfbi, Ecm1                                                          | 0.016          |
|                  | ECM Protease Inhibitors#                                 | 7    | 0.004          | Thbs1, Timp3                                                                      | 0.006          |
|                  | TGF-β Activin-responsive e                               | 16   | 0.010          | Junb, Fos, Tgfbi, Pdgfb, Tgfbi11, Igf1                                            | 0.014          |
|                  | Other Regulators of Cell Differentiation (Neural Specification) # | 17   | 0.003          | Elavl3, Neurod1, Neurod4, Nhlh1, Neurog1, Nhlh2, Neurog3, Spock2, Neurog2           | 0.004          |
|                  | Other Related growth Factor^                              | 7    | 0.005          | Ctgf, Igf1                                                                       | 0.015          |
|                  | Other Related growth Factor#                             | 7    | 0.040          | Ctgf Hgf Igf1                                                                     | 0.008          |

^= Gene set is reduced in ALC (all alcohol group) as compared with Control.
# = Gene set is reduced in ALC-NTO as compared with Control.
*= Gene set is reduced in ALC-NTC as compared with Control.

ECM: extracellular matrix.
Validation by Quantitative RT-PCR

Quantitative RT-PCR (qRT-PCR) was used to verify some of the genes that were significantly affected by alcohol, including a sample of genes from the functional gene sets for neural specification and trophic factors identified in GSEA (Tables 6 and 7). These studies used independent embryos subjected to identical ethanol exposure. The qRT-PCR verified that all 11 down-regulated neural specification genes (Table 6) and neurotrophic/growth factor genes (Table 7) tested differed in the same direction. One gene (Mylc2) that did not differ in the microarray experiments was also tested and the lack of difference was confirmed.

Discussion
1. Developmental Deficits and Correlation with Gene Expression Profiles

The abnormal embryonic development resulting from the alcohol treatment at this specific stage of development (Figure 1; Table 1) was consistent with our previous report [29] and those of others [41,42]. Two different facets of abnormal development could be identified: growth delay and frank teratogenesis. Delays in growth were also evident by the significant reductions in the total RNA per embryo and in the delayed morphological staging (Table 1). The affected structures were derived from each of the three germ layers, i.e., neural tube and brain vesicles (ectoderm), somites and cardiovascular system (mesoderm/endoderm), and involved a wide range of tissues and organs (e.g., heart, head, limbs). Alterations in all of these have been observed in FAS cases. The teratogenic consequences were evident as dysmorphism of various organs (central nervous system, eye, and heart) that involved pathogenic effects beyond just the observed delay of the normal course of development. Examples include enlarged heart primordium and abnormally enlarged ventricular chambers, detached pericardial sac, small forebrain, flat telencephalic vesicle, failure in neural tube closure, and small and irregularly shaped eyes.

Neural tube defect

We observed in Experiment 1 that gene expression profiles from alcohol treatment of embryos in this controlled culture system yielded two distinguishable patterns; comparison to the morphological data revealed that these were correlated with two different phenotypes: open (ALC-NTO) and closed neural tubes (ALC-NTC). The phenotypes and correlated gene expression differences were reproduced in Experiment 2. The embryos with open neural tubes (ALC-NTO) had more severe delays in brain and otic development than those with closed neural tubes (ALC-NTC) (Table 1). These different phenotypes are consistent with our previous in vivo observation in a liquid diet model of prenatal alcohol exposure in C57BL/6 mice, which resulted in partial penetration of incomplete neural tube closure (as late as embryonic day 15) and a cascade of deficits in midline structural development [43]. Finding this difference in development in experimentally controlled culture conditions indicates either a stochastic event or that an extremely sensitive gene-environment interaction is involved, e.g. different outcomes based on small differences in developmental stage at the time of exposure or small differences in tissue concentrations of alcohol across embryos. We have recently found greater DNA hypermethylation in ALC-NTO than in ALC-NTC embryos, particularly in genes on chromosomes 7, 10, and X. Remarkably, there was a >10 fold increase in the number of hypermethylated genes on chromosomes 10 and X in ALC-NTO than ALC-NTC [34].

Both the ALC-NTC and the ALC-NTO embryos demonstrated lower expression of genes in sets related to cell growth, growth factors, heart (angiogenesis), and eye (in NTC vs. Control) (Table 4; Table 7). The ALC-NTC and ALC-NTO embryos also differed in other sets of functionally related genes. The histone gene set was selectively reduced in ALC-NTO compared to controls. The epidermal growth factor signaling pathway genes were lower in ALC-NTO than ALC-NTC (Table 4). At the single gene analysis level, Experiment 2 showed a greater number of neurotrophic/growth factor genes were down-regulated in ALC-NTO than in ALC-NTC groups, particularly in the TGFβ, NTF3, S100, and EGF families. These differences in gene expression between the ALC-NTO and ALC-NTC embryos appear to be correlated with the more severe teratogenic trajectory of the ALC-NTO group, but causal relationships have yet to be established.

Table 6 RT-PCR confirmation of differences in gene expression: Neural specification genes from Experiment 1

| Gene | GenBank | Fold Change* | p-value* | Fold Change | p-value | Description |
|------|---------|--------------|----------|-------------|---------|-------------|
| Bhlhb5 | NM_021560 | -1.6 | 0.0021 | -2.3 | 0 | basic helix-loop-helix domain, class B5 |
| Ngn2 | BC055743 | -2 | 0.0015 | -2 | 0 | neurogenin 2 |
| Ngn1 | NM_010896 | -1.3 | 0.047 | -1.7 | 0.021 | neurogenin 1 |
| Sox5 | AL528773 | -1.4 | 0.005 | -1.7 | 0.005 | SRY-box containing gene 5 |
| Mylc2 | NM_023402 | -1 | 0.19 | -1 | 0.19 | myosin light chain |

*Control versus alcohol-treated.
The neural tube abnormality may either be a delay in neural tube closure or a neural tube defect. In either case, a delay in closing of the neural tube is associated with deficits in midline brain development due to disruption of the timing of critical events of early brain development. At more mature stages, such midline deficits include craniofacial abnormalities, corpus callosum, olfactory bulb, cerebellum, and raphe neuron formation [43-50].

2. Patterns of Gene Expression

A. Temporal patterns

Green and colleagues [27] reported that a 3 to 4 h binge-like alcohol exposure, with blood alcohol concentration 300 to 400 mg/dL at E8, produced a major abnormality in craniofacial and eye development in C57BL/6 mice at E15 or E17 (effects in the C57BL/6J substrain were greater than in the C57BL/6N substrain). Alterations of gene expression were reported to occur within hours of alcohol exposure at E8; these genes included metabolic and cellular gene, down-regulated ribosome and proteasome pathways; upregulated glycolysis and pentose phosphate, tight junction, and Wnt signaling pathways, as well as other cellular profile genes. In another study, a comparable high dose of alcohol exposure at an earlier stage, E6-E8, produced growth retardation, abnormal tail torsion, open neural tube, reduction of somite number, and other malformations [28]. The altered gene expression at E10 included cytoskeletal (Neurofilament), signal transduction (Zinc finger protein, MAP kinase related, Transcription factor NF212), and metabolic genes (lactate dehydrogenase, Aldolase 1). In the current study, a similar dose of alcohol exposure at the stage of neurulation (E8-10) produced a major neural and cardiovascular retardation and other organ system abnormalities. The trends of gene expression are consistent with the observed developmental delay and growth retardation in FASD. Among the genes with reduced expression in the alcohol-treated embryos were those involved in growth retardation, neural development, heart and hematopoiesis, and epigenetics. Among the identified functionally related gene sets, the most notable effect was the down regulation of growth-related genes, which represented the largest group of affected genes (Table 4). These genes provide plausible candidates for mechanistic links to the observed embryonic growth retardation.

B. Neural specification genes

Expression of neural specification genes (Table 5 and 7) and neurotrophic/growth factor genes (Table 4 and 7) was also reduced by the ethanol exposure. These participate in neuronal specification, neural stem cell differentiation, and neural fate determination [51-55]. Suppression of these genes predicts a downstream reduction in the early formation of neural cells. Null neurog 1 (Ngn1) or neurog 2 (Ngn2) leads to sensory abnormality [56,57]). These differential expression of neuronal specification/patterning genes together with neurotrophic genes supports the dysmorphism and developmental delay of neural tube and fore-to midbrain formation. The Igf1 and EGF genes were also identified by a microarray study with 3 h alcohol treatment [27] indicating they are altered early after ethanol exposure. The down-regulation of these neuronal specification and neural trophic/growth factor genes may play a major role in the neurodevelopmental deficit observed in the current study and featured in FASD.

C. Genes related to other organ defects

Although heterogeneity of tissue arising from use of whole embryos might have masked some changes in specific tissues, two functional gene sets, optic vesicle and the heart (Table 4), were identified and specifically linked to our observed developmental delay and abnormalities. Also, the collective down-regulation of key hematopoiesis genes that were either absent (Table 3) or reduced (Table 2) is consistent with the reduced blood circulation observed in the embryos.

D. Histone variants

Many histone genes related to epigenetic regulation of transcription were affected by ethanol (Table 4). The
reduction of many histone variants would alter chromatin organization, affecting transcription at a global level [58,59]; this may be an important effect of the alcohol that leads to the reduction of total RNA and induced growth retardation. Modification of epigenetic processes is a potential mechanism by which alcohol may alter gene expression during development, and may be an important candidate mechanism for the pathophysiology of fetal alcohol syndrome.

**E. Alcohol delayed or induced gene expression**

Other genes that were present in the control group but absent in the alcohol-treated group (Table 3) likely reflect a delay in onset or a strong inhibition of normal expression at this stage of development. Among them, four hematopoiesis genes [glycophorin A (*Gypa*), adducin 2 (*Add2*), beta-2 microglobulin (*B2m*), and ceruloplasmin (*Cp*)] associated with blood cell formation were absent in the alcohol-treated groups; these genes are key components in the pathway of white and red blood cell formation [36,38,60-62]. The absence of these genes is in agreement with the low circulating blood cells seen in alcohol treated embryos (Figure 2). The expression of aldehyde dehydrogenase 1B1 (*Aldh1b1*) was induced in both of our experiments by alcohol treatment during this period of early neurulation (Table 2 last row). Because *Aldh1b1* encodes an efficient enzyme for breakdown of acetaldehyde formed during metabolism of ethanol, this up-regulation is likely a detoxification response to the high level of ethanol in the environment. However, the metabolism of other substrates of this enzyme (e.g., retinoic acid, corticosteroids, biogenic amines, neurotransmitters, and lipids) that are required for normal development may be adversely affected by this increase in *Aldh1b1* expression [63,64].

**Conclusion**

In summary, alcohol exposure during the period of early neurulation at ~E8-E10, is predominantly inhibitory to gene expression, particularly the neural developmental genes. We found major reductions in gene sets involved in neurospecification, neural growth factors, cell growth and hematopoiesis. These effects on gene expression parallel the growth delay and developmental abnormalities including brain, neural tube, eye, heart, blood cells, and embryonic vascularization which are major targets in FASD. Our study, in conjunction with others that use different developmental periods of alcohol exposure, provides an important portfolio of alcohol-induced changes in gene expression associated with altered development. Together, these gene profiles should contribute to the generation of testable new hypotheses concerning the mechanistic path from gene expression changes to embryonic structural deficits, and for causal mechanisms of alcohol-induced teratogenesis (e.g., brain growth retardation, neural tube midline deficit, craniofacial dysmorphology) in fetal alcohol spectrum disorder. Two such hypotheses emerge from the current study. The first is that alcohol causes a delay in development of the nervous system by inhibiting specific sets of genes involved in neural development (*Ngoi*, *Nhlh*, *Sax*, *Igf*, *Ntf*, and *Egf*). The second is that neural tube defects are mediated by the inhibition of genes in the epidermal growth factor signaling pathway and genes encoding histone variants.

**Methods**

**Embryonic Culture**

All experimental procedures were approved by the Institutional Animal Care and Use Committee of the Indiana University School of Medicine (Indianapolis, IN) and are in accordance with the guidelines of the Institutional Animal Care and Use Committee of the National Institute on Drug Abuse, National Institutes of Health, and the Guide for the Care and Use of Laboratory Animals [65]. Two-month-old C57BL/6 mice (~20 g) were purchased from Harlan, Inc. (Indianapolis, IN). Upon arrival, breeder mice were individually housed and acclimated for at least one week before mating began. The mice were maintained on a reverse 12 h light-dark cycle (lights on: 19:00 - 07:00) and provided with laboratory chow and water ad libitum. Two females were placed with one male for two hours between 08:00 and 10:00. When a vaginal plug was detected after the mating period, it was designated as embryonic day 0 (E0). On E8.25 at 15:00, dams were sacrificed using CO2 gas. The embryos were treated at this stage, which is the beginning of neurulation. The window of 46 hrs treatment covered the stages of the formation of the major organs, neural specification and patterning. These stages are known to be vulnerable to alcohol [66].

The technique for whole embryo culture was based on the methods described by New [31]. The gravid uterus was removed and placed in sterile PBS (0.1 M phosphate buffer containing saline) at 37°C. The embryo in the visceral yolk sac along with a small piece of the ectoplacental cone (hereafter called embryo, unless otherwise stated) was carefully removed from the deciduas tissues and the Reichert’s membrane in PBS containing 4% fetal bovine serum (Sigma, St Louise. MO). After removal, three embryos bearing 3-5 somites (E8.25) were incubated in a culture bottle in 20 mL of medium which consisted of 70% immediately centrifuged heat-inactivated rat serum (Harlan Sprague-Dawley, Inc, Indianapolis, IN) and 30% phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 0.5 mM MgCl2, 8 mM Na2HPO4, 1.47 mM KH2PO4, 0.9 mM CaCl2, 5.6 mM glucose, 0.33 mM sodium pyruvate, pH7.4) supplemented with 20 units/ml penicillin and
We thought that obtaining a complete gene expression profile in parallel with this widespread alcohol-induced teratogenesis in the embryo would be informative.

Embryonic dysmorphology

The analysis of embryo dysmorphology was performed as described by van Maele-Fabry et al. [71] and in our previous report [29]. The morphological features of the developing embryo, including the allantois, flexion, heart, caudal neural tube, hind-brain, midbrain, fore-brain, otic system, optic system, branchial bars, maxillary process, mandibular process, forelimb, hindlimb, and somites, were examined and scored for any malformations using the ordinal scales of our previous report [29]. Scores for each of the above features were typically not normally distributed, so they were analyzed statistically by the non-parametric Mann-Whitney U test. The number of somites was normally distributed, so those data were analyzed by Student’s t-test, using StatView software (SAS Institute, Inc., Cary, NC).

Gene expression analyses

Two microarray experiments were performed. In Experiment 1, total RNA was isolated from individual whole embryos (4 vehicle control, 4 alcohol treated). Each embryo was immediately immersed in 700 ml TRIZol (Invitrogen) and homogenized using a Polytron. Extraction followed the TRIZol protocol. Ethanol precipitated RNA was resuspended in DEPC water. RNA was cleaned up using RNeasy mini-kit (Qiagen, Valencia, CA). The quality of RNA was assessed by the Agilent Bioanalyzer (Agilent Technologies, Waldbronn, Germany) and by spectrophotometry from 220 nm to 350 nm; concentration was determined from A260. Typical total RNA yields were 5-10 μg/embryo. Microarray analysis was performed at the Center for Medical Genomics at the Indiana University School of Medicine. Labeling and hybridization to Affymetrix Mouse Genome 430A GeneChips® (Affymetrix, Santa Clara, CA) were carried out following the manufacturer’s suggested procedure. Fragmented biotinylated RNA from each embryo was separately hybridized to its own GeneChip for 17 hours at 42°C. The microarray analysis revealed striking differences among the 4 alcohol treated samples, which segregated as two separate pairs rather than one set of four; subsequently, it was noted that one pair of embryos had an open neural tube (ALC-NTO) and the other pair had the neural tube closed (ALC-NTC). All 4 control embryos had closed neural tubes.

Experiment 2 was designed to follow-up these initial results and provide an independent test of the gene expression correlations with the two neural tube phenotypes. Total RNA was isolated from individual embryos (4 vehicle control, 7 alcohol treated: 4 ALC-NTO, 3 ALC-NTC).
RNA extraction and microarray analysis was as described above, except that Affymetrix Mouse Genome 430 2.0 GeneChips® (Affymetrix, Santa Clara, CA) were used.

The Mouse Genome 430A chip contains over 22,600 probe sets representing transcripts and variants from over 14,000 well-characterized mouse genes. The newer Mouse Genome 430 2.0 Array contains all of the probe sets present on the earlier 430A chip plus additional probe sets for a total of approximately 45,000 probe sets that analyze the expression of over 39,000 transcripts and variants from over 34,000 well-characterized mouse genes. The differences in feature size and probe set content make direct comparisons inappropriate, due to scanning and scaling issues, but because the probe sets on the 430A are present on the 430 2.0 array, those can be compared at the level of gene lists.

The data from independent arrays (each with RNA from a single embryo) for each of the treatments were extracted using the Affymetrix Microarray Suite 5.0 (MAS5) algorithm. Data for both experiments have been deposited in GEO/NCBI and have been assigned series accession number GSE9545 and sample numbers GSM241642 through GSM241660.

To minimize false positive results, only genes detected ('present' by the MAS5 algorithm) on at least half of all individual arrays in at least one experimental condition were retained for further analysis. This avoids data that primarily represent "noise" [72,73].

To detect differentially expressed genes, control samples were compared to ALC-NTC samples, or ALC/NTO, samples, or their combination, using a Welch's t-test on the log-transformed signals. To see genes that were similarly affected in both experiments, we intersected the gene lists. To avoid missing genes that met a stringent significance threshold in one experiment but were just beyond that threshold in the second, we chose p ≤ 0.05 as the threshold for each experiment. Given that the two experiments were independent, the probability that a gene overlaps by chance and differs in the same up/down direction in both experiments is (0.05)* (0.05)/2 = 0.00125. False discovery rate (FDR) was calculated based on the number of genes expected to be significant and in the same direction in both experiments under the null hypothesis/the number of such genes actually found.

Hierarchical clustering with average linkage function was used to construct a dendrogram based upon all genes that were present on at least half of the arrays in an experimental group.

Gene Set Enrichment Analysis (GSEA) [74,75] was carried out to identify groups of related genes that were differentially expressed. GSEA analyses were conducted for 4 different comparisons: control vs. ALC, control vs. ALC/NTO, control vs. ALC/NTO, and ALC/NTO vs. ALC/NTO. The top ranked genes in a significant gene set, in the region up to the maximum score, were considered significant. To reduce multiple testing issues, the GSEA in this study was conducted using two gene set databases designed to test the hypotheses that groups of genes related to Early Development or Stem Cells were differentially affected by alcohol.

(a) Early Developmental Biology Gene Sets (Additional file 1): 415 GO categories that were defined by 29 key words were selected (identified gene sets, Additional file 2).

(b) Stem Cell Related Gene Sets: 191 GO categories related to stem cells, neurogenesis, osteogenesis, extracellular matrix, developmental signal transduction pathway, cell cycle, growth factor, TGFβ/BMP signaling, Wnt signaling, and notch signaling were developed by Superarray Bioscience http://www.superarray.com. The gene set information is listed in Additional file 3 (shown with consent of Superarray Bioscience, Frederick, MD).

| Table 8 Primers for qRT-PCR |
|-----------------------------|
| Primer | Sequence | RefSeq ID |
| Bhlhb5-f | CCAATTCAGCGAGGCACGCTGTC | NM_021560 |
| Bhlhb5-r | GCCCTCACTTCCCTGTCAATGGC | NM_021560 |
| Ctfg-f | AGATGGGAGATTAGCTGACGCAAGAG | NM_010217 |
| Ctfg-r | TCGAGCAAGTGACATCGTTATTTG | NM_010217 |
| Dll 1-f | ATAGCCGACTGAGGTGATAGTGAAGC | NM_007865 |
| Dll 1-r | CTGCGCTGAAACGCTTTCTCAG | NM_007865 |
| Efemp1-f | TCTACCTACGACGAAAAACCCTGTG | NM_146015 |
| Efemp1-r | AGAGCTTTGGAAAGGTGTTCTTAC | NM_146015 |
| Gapdh-f | TCCTGATGACGAAATGATGACG | NM_008084 |
| Gapdh-r | TCTGTCGCTATCGTCTTCGT | NM_008084 |
| Igf1-f | ACTGACATGGGAGAAGCTACAGTACGTG | NM_184052 |
| Igf1-r | TGGCTCGCGATCCTCTCTCGTCTC | NM_184052 |
| Igfbp2-f | CAGAGCGAGTGTGACGATGATG | NM_008342 |
| Igfbp2-r | CAGCTTCTTCTATGAGCTTTACG | NM_008342 |
| Ntf3-f | TCGTTACTCCGGACCGATCAGTACGGGAG | NM_007847 |
| Ntf3-r | CTCCCTGTATGCTGCTGGCC | NM_007847 |
| Neurog2a-f | GAGAGTCTCAAGCAGCCTCCTC | NM_023402 |
| Neurog2a-r | ACTGTGACCAATGGTGCC | NM_023402 |
| Neurog1-f | TCCCTCGGATCCTCGAGACGATACCTC | NM_010896 |
| Neurog1-r | AAGCTGCGATTGAATGGGAGAAGACG | NM_010896 |
| Neurog2-f | CCATCGGCTGCTCAGAATCTGTG | NC_055743 |
| Neurog2-r | TCCGCAGGGAGAGATACCTC | NC_055743 |
| Sox5 f | AATGATGGGAGATGGATTGAGCAAGACG | A528773 |
| Sox5 | GCCATCTGGTGGAGCTTTTTGTTTTG | A528773 |
| Tie1-f | CAGTCGCCAGCTTGTTAAGACG | NM_013692 |
| Tie1-r | GCAGATCGGAGAAGATTGAGAAG | NM_013692 |
| Edil3-f | GATTCAGGCTGTCAAGACCTTGTG | AF031524 |
| Edil3-r | GGCTGCGCTGCTGCAAGAATTGAG | AF031524 |

Primers are named according to the gene with-f for forward primer and -r for reverse primer.
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

A number of differentially expressed genes detected in Experiment 1 were selected for qRT-PCR validation based on their biological significance. To test selected genes from the neural specification gene group, the total RNA of each embryo was isolated using the RNeasy mini kit (Qiagen, Valencia, CA) as described above. Vector NTI Advance 9.0 software (Invitrogen, Frederick, MD) was used to design the primers for qRT-PCR (Table 8); if possible, at least one primer in each pair spanned an exon-intron boundary. The number of embryos used in the control group varied from 7 to 9 for different genes, and the number used in the alcohol treated group varied from 9 to 11. The cDNA templates were generated from 50 ng total RNA (TaqMan Reverse Transcription Reagents, Applied Biosystems, Foster City, CA) from each individual embryo, and added to PCR reactions that contained 0.1 µM of forward and reverse primers and SYBR Green PCR Master Mix (Applied Biosystems). Triplicate qRT-PCR were performed for each sample in at least 3 experiments (n = 9). The cycle threshold (Ct) for each cDNA template was determined on the ABI Prism 7700 Sequence Detection System. The Ct refers to the cycle number at which the fluorescence of the amplified product reached an arbitrary threshold that was within the exponential phase of amplification. To correct for sample-to-sample variation, Gapdh served as an internal reference. Relative values of expression of neural specific genes were determined for each sample using the ΔΔCt method [76], and these values were normalized to the Ct values of Gapdh. The average Gapdh Ct values for alcohol treatment and control were the same in each tested sample, making it an appropriate control gene to normalize the expression of the candidate genes of interest.

After Experiment 2, we decided to test the three groups (control, ALC/NTO, ALC/NTC) as pools, and chose growth/neurotrophic genes. A separate experiment was carried out with embryonic treatments identical to those used in Experiment 1. Whole embryos were homogenized in TRIzol (Invitrogen) using a Mini-Bead-Beater-8 (Bipspec products, INC, Bartlesville, OK), and total RNA isolation was as described above. Two different pools were created for each condition: Control1 (n = 12), ALC/NTC1 (n = 16), ALC/NTO1 (n = 5), Control2 (n = 5), ALC/NTC2 (n = 9), ALC/NTO2 (n = 6). The relative quantification of expression of each RNA pool was performed using the ABI Prism 7700 Sequence Detection System and calculated using the standard curve method (Applied Biosystems, User Bulletin #2; http://www.appliedbiosystems.com). In each experiment, a relative expression level was determined for the two pools from each group in triplicate; 3-4 repeat experiments were performed, resulting in 18-24 values from each group. The treatment groups were compared with one way ANOVA followed by Student’s t test.

Additional material

Additional file 1: Keyword and GO categories. List of keywords used and the GO categories identified by these key words for Early Development.

Additional file 2: GO gene sets selected by keywords. List of gene sets used in GSEA analyses, derived from GO categories selected by key words for Early Development. Title of each set followed by Entrez Gene IDs of the genes in the set.

Additional file 3: GO categories related to Stem Cells. Gene sets used in GSEA analysis based on GO categories related to Stem Cells. Title of each set followed by Entrez Gene IDs of the genes in the set.

Acknowledgements

This study was supported by NIAAA P50 AA07611 to the Alcohol Research Center at Indiana University School of Medicine (Center PI, David W. Crabb; FAS project, Feng C. Zhou), and in part by AA016698 to FCZ. Microarray studies were carried out in the Center for Medical Genomics at Indiana University School of Medicine, which is partially supported by the Indiana Genomic Initiative at Indiana University (INGEN®); INGEN® is supported in part by the Lilly Endowment, Inc. We thank Ms. Li-jun Ni for her technical assistance in embryonic culture, and Ronald Jerome and Chunxiao Zhu for technical assistance in preparation of microarray.

Author details

1Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN, 46202, USA. 2Department of Medicine, Indiana University School of Medicine, 545 Barnhill Drive, Indianapolis, IN, 46202, USA. 3Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN, 46202, USA. 4Department of Psychology, Indiana University-Purdue University at Indianapolis 402 N. Blackford Street, Indianapolis, IN, 46202, USA.

Authors’ contributions

FCZ involved in the overall design and coordination of the study. CG involved in the design of the experiment. QZ and LL carried out the statistical analysis, and YL the informatics. TL performed RTPCR analysis. HJE and JMN were involved in experimental design and carried out the microarray study. All authors participated in the writing of the manuscript. All authors read and approved the manuscript.

Received: 6 September 2010 Accepted: 21 February 2011 Published: 21 February 2011

References

1. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973, 2(7836):999-1001.
2. Sampson PD, Streissguth AP, Bookstein FL, Little RE, Claren SK, Dehaene P, Hanson JW, Graham JM Jr. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology 1997, 56(5):317-326.
3. Claren SK, Alvord EC jr, Sumi SM, Streissguth AP, Smith DW. Brain malformations related to prenatal exposure to ethanol. J Pediatr 1978, 92(1):64-67.
4. Kalter H. Teratology in the 20th century: environmental causes of congenital malformations in humans and how they were established. Neurotoxicol Teratol 2003, 25(2):131-262.
5. Stromland K, Hellstrom A. Fetal alcohol syndrome—an ophthalmological and socioeducational prospective study. Pediatrics 1996, 97(6 Pt 1):845-850.
6. Burd L, Deal E, Rios R, Adickes E, Wynne J, Klag MG: Congenital heart defects and fetal alcohol spectrum disorders. Congent Heart Dis 2007, 2(4):250-255.
7. Climent E, Pascaul M, Renau-Piqueras J, Guerr C: Ethanol exposure enhances cell death in the developing cerebral cortex: role of brain-derived neurotrophic factor and its signaling pathways. J Neurosci Res 2002, 68(2):213-225.
8. Miller MV, Kuhn PE: Cell cycle kinetics in fetal rat cerebral cortex: effects of prenatal treatment with ethanol assessed by a cumulative labeling technique with flow cytometry. Alcohol Clin Exp Res 1995, 19(1):233-237.
9. Ikonomidou C, Bittigau P, Ishimaru MJ, Wozniak CF, Koch C, Genz K, Price MT, Stefankova V, Horster F, Tenkova T, et al: Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000, 287(5455):1056-1060.
10. Light KE, Belcher SM, Pierce DR: Time course and manner of Purkinje neuron death following a single ethanol exposure on postnatal day 4 in the developing rat. Neuroscience 2002, 114(2):327-337.
11. Holownia A, Ledig M, Menez JF: Ethanol-induced cell death in cultured astroglia. Alcohol Clin Exp Res 1999, 17(2):359-365.
12. Sulik KK: Genetics of alcohol-induced craniofacial dysmorphism. Exp Biol Med (Maywood) 2005, 230(6):366-375.
13. Kilburn BA, Chiang PJ, Wang J, Flintke CR, Smith SM, Armand DR: Rapid induction of apoptosis in gastrulating mouse embryos by ethanol and its prevention by HB-EGF. Alcohol Clin Exp Res 2006, 30(1):127-134.
14. Smith SM: Alcohol-induced cell death in the embryo. Alcohol Health Res World 1997, 21(4):287-297.
15. Goodlett CR, Horn KH, Zhou FC: Alcohol teratogenesis: mechanisms of damage and strategies for intervention. Exp Biol Med (Maywood) 2005, 230(6):394-406.
16. Ritsa L, Towlar DA, Avoli LV: Gestational exposure to ethanol suppresses msx2 expression in developing mouse embryos. Proc Natl Acad Sci USA 1997, 94(14):7499-7504.
17. Ahlgren SC, Thakur V, Bronner-Fraser M: Alcohol teratogenesis: mechanisms of damage and strategies for intervention. Exp Biol Med (Maywood) 2005, 230(6):394-406.
18. Yamada Y, Nagase T, Nagase M, Koshima I: Gene expression changes of sonic hedgehog signaling cascade in a mouse embryonic model of fetal alcohol syndrome. The Journal of Craniofacial Surgery 2005, 16(6):1653-1661, discussion 1662-1053.
19. Poggi SH, Goodwin K, Hill JM, Brennan DE, Tendel E, Schnelli S, Abebe D, Spong CY: The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol 2003, 189(3):799-805.
20. Xu Y, Xiao R, Li Y: Effect of ethanol on the development of visceral yolk sac. Hum Reprod 2005, 20(9):2509-2516.
21. Xu Y, Chen X, Li Y: Edc11, a gene of SNF2 family, may play a role in the teratogenic action of alcohol. Toxicol Lett 2005, 157(3):233-239.
22. Lee U, Soh Y, Song BI: Molecular characterization of fetal alcohol syndrome using mRNA differential display. Biochem Biophys Res Commun 1997, 240(1):293-313.
23. Hard ML, Abdolell M, Robinson BH, Koren G: Environmental and molecular mutagenesis of anterior neural tube closure. Alcohol Clin Exp Res 2002, 269(3):389-395.
24. Coulter CL, Leech RW, Schaeffer GB, Scheithauer BW, Brumback RA: Midline corpus callosum is a neuroanatomical focus of fetal alcohol damage. Anat Rec 2002, 269(3):162-174.
25. Sowell ER, Mattson SN, Thompson PM, Jeremie LN, Riley EP, Toga AW: Mapping callosal morphology and cognitive correlates: Effects of heavy prenatal alcohol exposure. Neurology 2001, 57(2):235-244.
26. Erkelen NL, Gallegue RA, Dusse MJ: Effects of in utero ethanol exposure and maternal treatment with a S-HT1A agonist on 51008-containing glial cells. Brain Res Dev Brain Res 2000, 121(2):133-143.
27. Couter CL, Leech RW, Schaeffer GB, Scheithauer BW, Brumback RA: Midline cerebral dysgenesis, dysfunction of the hypothalamic-pituitary axis, and fetal alcohol effects. Arch Neurol 1995, 50(7):771-775.
28. Sulik KK, Johnston MC, Daff PA, Russell WE, Dehant DB: Fetal alcohol syndrome and 2H4Geh1B8 anomaly: critical ethanol exposure periods for craniofacial malformations as illustrated in an animal model. Am J Med Genet Suppl 1986, 2:97-112.
29. Johnston VP, Swayne WW, Sato Y, Andreason NC: Fetal alcohol syndrome: craniofacial and central nervous system manifestations. Am J Med Genet 1996, 61(4):329-339.
30. Zhou FC, Sato Y, Powrzwczek T, Goodlett CR, Li TK: Moderate alcohol exposure compromises neural tube midline development in prenatal brain. Developmental Brain Research 2003, 144:43-55.
31. Bookstein FL, Sampson PD, Connor PD, Streissguth AP: Environmental and molecular mutagenesis of craniofacial and central nervous system manifestations. Am J Med Genet 1996, 61(4):329-339.
54. Kageyama R, Ohtsuka T, Hatakeyama J, Ohsawa R: Roles of bHLH genes in neural stem cell differentiation. Experimental cell research 2005, 306(2):343-348.

55. Lee JE: NeuroD and neurogenesis. Dev Neurosci 1997, 19(1):27-32.

56. Fode C, Gradwohl G, Morin X, Dierich A, LeMeur M, Gondis C, Guillemon F: The bHLH protein NEUROGENIN 2 is a determination factor for epibranchial placode-derived sensory neurons. Neuron 1998, 20(3):483-494.

57. Ma Q, Anderson DJ, Fritzsche B: Neurogenin 1 null mutant ears develop fewer, morphologically normal hair cells in smaller sensory epithelia devoid of innervation. J Assoc Res Otolaryngol 2000, 1(2):129-145.

58. Strahl BD, Allis CD: The language of covalent histone modifications. Science 2000, 289(5487):2204-2207.

59. Berger SL: Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002, 12(2):142-148.

60. Nehr V, Drenckhahn D, Joshi R, Bennett V: Adducin in erythrocyte precursor cells of rats and humans: expression and compartmentalization. Blood 1991, 78(7):1692-1696.

61. Bernier GM: beta 2-Microglobulin: structure, function and significance. Genet Dev 2002, 16(2):124.

62. Chang YZ, Qian ZM, Wang K, Zhu L, Yang XD, Du JR, Jiang L, Ho KP, Bernier GM: beta 2-Microglobulin: structure, function and significance. Genet Dev 2002, 16(2):124.

63. Duester G: Tissue distribution, ontogeny, and regulation of microsomal enzyme inducers in mice. Toxicol Sci 2008, 101(1):51-64.

64. National-Academy-of-Sciences: Guide for the care and use of laboratory animals. 7 edition. Washington, D.C.: National Academy Press; 2010.

65. Dunty WC jr, Chen SY, Zucker RM, Dehart DB, Sulik KK: Guide for the care and use of laboratory animals. 7 edition. Washington, D.C.: National Academy Press; 2010.

66. Webster W, Walsh D, Lipson A, McEwen S: Handbook of Drug and Alcohol Abuse. New York: Oxford University Press; 1975:95-128.

67. Wilkemeyer M, Chen SY, Menkari CE, Brenneman DE, Sulik KK, Charness ME: Evolution of the developmental scores of sixteen morphological features in mouse embryos displaying 0 to 30 somites. The international journal of developmental biology 1992, 36(1):161-167.

68. McClintick JN, Jerome RE, Nicholson CR, Crabb DW, Edenberg HJ: Reproducibility of oligonucleotide arrays using small samples. BMC Genomics 2003, 4(1):4.

69. Hoffman F: Generalized depressants of the central nervous system. In A Handbook of Drug and Alcohol Abuse. Edited by: Hoffman F, Hoffman A. New York: Oxford University Press; 1975:95-128.

70. Lindblad B, Olsson R: Unusually high levels of blood alcohol? JAMA 1976, 236(14):1600-1602.

71. van Maale-Fabry G, Delhaise F, Picard JJ: Effects of development and iron status on ceruloplasmin compartmentalization. J Biol Chem 1979, 254(16):7003-7010.

72. McGeary JE, Ewton LG, Cavanaugh SR, Ewton R: Unusually high levels of blood alcohol? JAMA 1976, 236(14):1600-1602.

73. van Maale-Fabry G, Delhaise F, Picard JJ: Evolution of the developmental scores of sixteen morphological features in mouse embryos displaying 0 to 30 somites. The international journal of developmental biology 1992, 36(1):161-167.

74. McClintick JN, Jerome RE, Nicholson CR, Crabb DW, Edenberg HJ: Reproducibility of oligonucleotide arrays using small samples. BMC Genomics 2003, 4(1):4.

75. McClintick JN, Edenberg HJ: Effects of filtering by Present call on analysis of microarray experiments. BMC Bioinformatics 2006, 7:49.

76. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.